Patrick Mahaffy, Clovis CEO (Kathryn Scott Osler/The Denver Post via Getty Images)
That big R&D PARP win Clovis CEO Mahaffy touted a few weeks ago? The FDA isn't buying it
Once again, you’ll have to go to the fine print in an SEC filing to find the bad news that has been steadily killing Clovis Oncology’s share price for years.
Just weeks after Clovis did its level best to trumpet a big win for its stunted cash calf Rubraca in a Phase III ovarian cancer study, you can go to the SEC site to see why its bruised and battered stock price is getting pummeled one more time.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.